Clearing the air: A review of our current understanding of "chemo fog"

Current Oncology Reports

Volumn 15, Issue 3, 2013, Pages 260-269

  O'Farrell, Erin ^a   MacKenzie, Joyce ^b   Collins, Barbara ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adjuvant chemotherapy; Chemo fog; Chemobrain; Chemotherapy related cognitive impairment; Cognitive function

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIESTROGEN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVOR; CHEMOTHERAPY RELATED COGNITIVE IMPAIRMENT; COGNITIVE DEFECT; CONTROL GROUP; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DEPRESSION; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG PENETRATION; ESTROGEN SYNTHESIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC RISK; GRAY MATTER; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MENTAL FUNCTION; METHODOLOGY; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROTEIN EXPRESSION; PSYCHOLOGIC ASSESSMENT; QUESTIONNAIRE; SELF REPORT; STUDY DESIGN; TREATMENT DURATION; WORKING MEMORY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEOPLASMS; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; QUALITY OF LIFE; RISK FACTORS; SELF REPORT; SURVIVORS;

EID: 84877923475     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0307-7     Document Type: Article

References (89)

1. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3:323-32.
2. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61-6.
3. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210-8.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
5. Maki P, Hogervorst E. HRT and cognitive decline. Best Pract Res Clin Endocrinol Metab. 2003;17:105-22.
6. Sherwin BB. Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci. 2012;126:123-7.
7. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422-30. doi: 10.1002/pon.964.
8. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14:995-8.
9. Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955-69.
10. Collins B, MacKenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early-stage breast cancer patients: a prospective study. Psychooncology. 2009;18:811-21.
11. Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage. 2004;21:364-71.
12. Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60-70.
13. Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61-6.
14. Palmer JL, Trotter T, Joy AA, et al. Cognitive effects of tamoxifen in premenopausal women with breast cancer compared to healthy controls. J Cancer Surviv. 2008;2:275-82.
15. Phillips KA, Aldridge J, Ribi K, et al. Cognitive function in post-menopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2011;126:221-6.
16. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exesestance on cognitive functioning of post-menopausal patients with breast cancer: results from the neuropsychological side study of the Tamoxifen and Exesestance Adjuvant Multinational Trial. J Clin Oncol. 2010;28:1294-300.
17. Shilling V, Jenkins V, Fallowfield L, et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405-12.
18. Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623-9.
19. Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703-8. An international task force was formed to establish guidelines for research in the area of cognition and cancer.
20. Cimprich B, Reuter-Lorenz P, Nelson J, et al. Pre-chemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32:324-31.
21. Schilder CM, Seynaeve C, Linn SC, et al. The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psychooncology. 2010;19:415-22.
22. Wefel JS, Lenzi R, Theriault R, et al. "Chemobrain" in breast carcinoma?A prologue. Cancer. 2004;101:466-75.
23. Stewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008;17:122-30.
24. Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog - methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95:125-9.
25. Ouimet LA, Stewart A, Collins B, et al. Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol. 2009;31:73-89.
26. Jansen CE, Cooper BA, Dodd MJ, et al. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19:1647-56.
27. Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care. 2012;21:485-92.
28. Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer. 2012;20:1361-75.
29. Hutchinson AD, Hosking JR, Kichenadasse G, et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38:926-34.
30. Pullens MJJ, DeVries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology. 2010;19:1127-38.
31. Iconomou G, Mega V, Koutras A, et al. Prospective assessment of emotional distress, cognitive function and quality of life in patients with cancer treated with chemotherapy. J Cancer. 2004;101:404-11.
32. Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10:120-4.
33. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12:267-75.
34. Scherling C, Collins B, MacKenzie J, et al. Pre-chemotherapy differences in visuo-spatial working memory in breast cancer patients compared to controls: an fMRI study. Front Hum Neurosci. 2011;5:122. doi: 10.3389/fnhum.2011.00122.
35. Scherling C, Collins B, MacKenzie J, et al. Pre-chemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34:543-60.
36. Scherling C, Collins B, MacKenzie J, et al. Structural brain differences in breast cancer patients compared to matched controls prior to chemotherapy. Int J Biol. 2012;4:3-25.
37. Hurria A, Somlo G, Ahles T. Renaming "chemobrain". Cancer Invest. 2007;25:373-7.
38. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274-81. This longitudinal study examined the relationship between changes in neuropsychological functioning and brain structure following chemotherapy and found significant correlations between these two measures.
39. Ganz PA. Doctor, will the treatment you are recommending cause chemobrain? J Clin Oncol. 2012;30:229-31.
40. Collins B, MacKenzie J, Tasca GA, et al. Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology. 2012. doi: 10.1002/pon.3163. This is a prospective longitudinal study of cognitive functioning after cumulative exposure to chemotherapy. Patients were assessed at the baseline and following each chemotherapy cycle. A linear decline in cognitive functioning was observed, supporting a dose-response relationship and suggesting that chemotherapy is a cause of cognitive disturbance.
41. Hedayati E, Alinaghizadeh H, Schedin A, et al. Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs. 2012;16:315-22.
42. Kreukels BPC, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005;94:53-61. doi: 10.1007/s10549-005-7093-3.
43. Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51:159-65.
44. Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98:1742-5. doi: 10.1093/jnci/djj470.
45. Ahles TA, Saykin AJ, Furstenberg T, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485-93. doi: 10.1200/JCO.20.2.485.
46. Brown MS, Simon JH, Stemmer SM, et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Am J Neuroradiol. 1995;16:2013-20.
47. Brown MS, Stemmer SM, Simon JH, et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Am J Neuroradiol. 1998;19:217-21.
48. Stemmer SM, Stears JC, Burton BS, et al. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol. 1994;15:1267-73.
49. Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev. 2011;35:729-41.
50. Winocur G, Henkelman M, Wojtowicz JM, et al. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res. 2012;18:3112-21.
51. de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206-19. doi: 10.1002/hbm.21102.
52. Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68:1447-53.
53. Silverman DH, Dy CJ, Castellon SA, et al. Altered fronto-cortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303-11.
54. Abraham J, Haut MW, Moran MT, et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8:88-91.
55. de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971-83. doi: 10.1002/hbm.21422.
56. Deprez S, Amant F, Yigit R, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32:480-93.
57. Ferguson RJ, McDonald BC, Saykin AJ, et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866-70.
58. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146-56.
59. Koppelmans V, de Ruiter MB, van der Lijn F, et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat. 2012;132:1099-106.
60. McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819-28. This was the first controlled prospective MRI study in the field of CRCI.
61. Lopez-Zunini RA, Scherling C, Wallis N, et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav 2012. doi: 10.1007/s11682-012-9213-0.
62. Jansen CE, Dodd MJ, Miaskowski CA, et al. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008;17:1189-95. doi: 10.1002/pon.1342.
63. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434-40. doi: 10.1200/JCO.2009.27.0827.
64. Kvale EA, Clay OJ, Ross-Meadows LA, et al. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial. Eur J Cancer Care. 2010;19:110-7. doi: 10.1111/j.1365-2354.2008. 01018.x.
65. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116:113-23. doi: 10.1007/s10549-008-0114-2.
66. Tager FA, McKinley PS, Schnabel FR, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2010;123:25-34.
67. Vearncombe KJ, Rolfe M, Wright M, et al. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009;15:951-62. doi: 10.1017/S1355617709990567.
68. Jansen CE, Miaskowski C, Dodd M, et al. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222-33.
69. Jansen CE, Miaskowski CA, Dodd MJ, et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairments in patients with breast cancer. Oncol Nurs Forum. 2007;34:997-1005.
70. Jim HSL, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578-87. This is a meta-analysis of 17 studies examining the long-term effects of chemotherapy on cognitive functioning. The results indicate cognitive deficits of small effect size in patients treated with chemotherapy as compared with healthy controls and patients not treated with chemotherapy.
71. Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychoogical effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76-89.
72. Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967-82.
73. Kopplemans V, Breteler MMB, Boogerd W, et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30:1080-6.
74. Kreukels BPC, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer. 2006;7:67-78.
75. Kreukels BPC, van Dam FSAM, Ridderinkhof KR, et al. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer. 2008;8:80-7.
76. Kreukels BPC, Hamburger HL, de Ruiter MB, et al. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol. 2008;119:533-41.
77. Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18:134-43.
78. Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: subjective complaints and objective neuropsychological test results. Psychooncology. 2009;18:775-82. doi: 10.1002/pon.1472.
79. Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late-onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348-56. doi: 10.1002/cncr.25098.
80. Heflin LH, Meyerowitz BE, Hall P, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst. 2005;97:854-6.
81. Heck JE, Albert SM, Franco R, et al. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc. 2008;56:1687-92.
82. Baxter NN, Durham SB, Phillips KA, et al. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc. 2009;57:403-11.
83. Du XL, Xia R, Hardy D. Relationship between chemotherapy use and cognitive impairments in older women with breast cancer. Am J Clin Oncol. 2010;33:533-43.
84. Mols F, Thong MSY, Vreugdenhil G, et al. Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology. 2009;18:1252-60.
85. Nieuwenhuijsen K, de Boer A, Spelten E, et al. The role of neuropsychological functioning in cancer survivors' return to work one year after diagnosis. Psychooncology. 2009;18:589-97.
86. Reid-Arndt SA, Yee A, Perry MC, et al. Cognitive and psychological factors associated with early post-treatment functional outcomes in breast cancer survivors. J Psychosoc Oncol. 2009;27:415-34.
87. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of ApoE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612-9.
88. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828-34.
89. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387-97.